An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vicarious Surgical Partners with Renowned Surgeon to Successfully Perform Two Cadaveric Ventral Hernia Procedures
Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
partnership
Rhea-AI Summary
Vicarious Surgical (NYSE:RBOT) announced the successful use of its Beta 2 prototype for cadaveric ventral hernia repairs by renowned surgeon Igor Belyansky. This milestone, showcasing advanced robotic surgical capabilities, is set to be highlighted on December 6, 2022, during Vicarious Surgical's Beta 2 Demonstration Day. The prototype aims to improve surgical efficiency and patient outcomes through minimally invasive techniques using a single-port approach. The collaboration with Belyansky underscores the company's commitment to innovation in robotic surgery.
Positive
Successful demonstration of the Beta 2 prototype by a renowned surgeon, indicating robust product development.
Focus on minimally invasive surgical techniques may attract interest from healthcare providers and investors.
Collaboration with an experienced surgeon enhances credibility and potential for future advancements.
Negative
None.
Surgeon Igor Belyansky, M.D., performs two successful cadaveric ventral hernia repairs using the Beta 2 Vicarious System
Highlights to be showcased at Vicarious Surgical’s Beta 2 Demonstration Day on December 6th, 2022
WALTHAM, Mass.--(BUSINESS WIRE)--
Vicarious Surgical Inc. (“Vicarious Surgical'' or the “Company”), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced that renowned surgeon Igor Belyansky, MD, used the Vicarious Surgical Beta 2 prototype, to successfully perform two cadaveric ventral hernia repair procedures.
“It’s incredibly exciting to work with the Vicarious Surgical team, and an honor to complete these procedures that we believe mark such an important milestone with the Beta 2 prototype,” Belyansky said. “The next frontier of robotic surgery is here and I look forward to the continued development of the innovative Vicarious Surgical robotic system.”
“We greatly value Dr. Belyansky’s expertise in the field of surgical robotics, and we are honored to collaborate with him on our first hospital-based Beta 2 prototype cadaveric procedures,” said Adam Sachs, CEO of Vicarious Surgical. “Our robotic system is designed with a focus on abdominal access and visualization through a single port the size of a dime, offering an unprecedented level of visibility and maneuverability - and we are immensely pleased to see these features at work in the operating room. We look forward to finalizing our novel minimally invasive design with direct surgeon feedback in mind; and we are excited to host Dr. Belyansky for a discussion of his Beta 2 experience at our upcoming investor event.”
Belyansky, MD, Chief of General Surgery at Anne Arundel Medical Center in Annapolis, has particular research interest in quality of life outcomes after hernia surgery. Dr. Belyansky is a strong proponent of patient education and informed decisions prior to surgery. He is a co-investigator of several research grants and has authored 16 publications, six book chapters, and several invited commentaries. He frequently presents at national and international surgical meetings and has received numerous research related awards. He is also a member of Vicarious Surgical’s 20 person-Surgeon Luminary Group, providing expertise and leadership to guide all clinical aspects of the Vicarious Surgical technology.
About Vicarious Surgical
Founded in 2014, Vicarious Surgical is a next generation robotics company developing a disruptive technology with the goals of increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and is backed by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai & Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.
